388 related articles for article (PubMed ID: 11489791)
1. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).
Mathijssen RH; van Alphen RJ; Verweij J; Loos WJ; Nooter K; Stoter G; Sparreboom A
Clin Cancer Res; 2001 Aug; 7(8):2182-94. PubMed ID: 11489791
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of irinotecan metabolism and transport: an update.
Smith NF; Figg WD; Sparreboom A
Toxicol In Vitro; 2006 Mar; 20(2):163-75. PubMed ID: 16271446
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.
Haaz MC; Rivory L; Riché C; Vernillet L; Robert J
Cancer Res; 1998 Feb; 58(3):468-72. PubMed ID: 9458091
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
5. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats.
Chu XY; Kato Y; Niinuma K; Sudo KI; Hakusui H; Sugiyama Y
J Pharmacol Exp Ther; 1997 Apr; 281(1):304-14. PubMed ID: 9103511
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of docetaxel : recent developments.
Baker SD; Sparreboom A; Verweij J
Clin Pharmacokinet; 2006; 45(3):235-52. PubMed ID: 16509758
[TBL] [Abstract][Full Text] [Related]
7. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
8. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from the irinotecan metabolic pathway.
Ma MK; McLeod HL
Curr Med Chem; 2003 Jan; 10(1):41-9. PubMed ID: 12570720
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
[TBL] [Abstract][Full Text] [Related]
11. Biliary excretion of irinotecan and its metabolites.
Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
[TBL] [Abstract][Full Text] [Related]
12. Modulation of irinotecan metabolism by ketoconazole.
Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
[TBL] [Abstract][Full Text] [Related]
14. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
15. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats.
Chu XY; Kato Y; Sugiyama Y
Cancer Res; 1997 May; 57(10):1934-8. PubMed ID: 9157988
[TBL] [Abstract][Full Text] [Related]
16. Determination of drug interactions occurring with the metabolic pathways of irinotecan.
Charasson V; Haaz MC; Robert J
Drug Metab Dispos; 2002 Jun; 30(6):731-3. PubMed ID: 12019202
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos A; Zanetta S; Cresteil T; Deroussent A; Pein F; Raymond E; Vernillet L; Risse ML; Boige V; Gouyette A; Vassal G
Clin Cancer Res; 2000 May; 6(5):2012-20. PubMed ID: 10815927
[TBL] [Abstract][Full Text] [Related]
18. Influence of phenytoin on the disposition of irinotecan: a case report.
Murry DJ; Cherrick I; Salama V; Berg S; Bernstein M; Kuttesch N; Blaney SM
J Pediatr Hematol Oncol; 2002 Feb; 24(2):130-3. PubMed ID: 11990699
[TBL] [Abstract][Full Text] [Related]
19. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
